Capecitabine Tablet
Product Images NDC 82009-112

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 82009-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container (Container)

Label for Capecitabine Tablets USP 500 mg oral tablets, containing 120 tablets per package. The label indicates a cytotoxic agent, Rx only, manufactured by Dr. Reddy's Laboratories Limited in India and labeled for Quallent Pharmaceuticals Health LLC. Storage instructions and dosage guidance are partially visible. The label includes barcodes and a 2D code area with serialization information.*

FDA Label Image

Figure1 (Figure1)

A survival curve chart comparing two treatment groups: Capecitabine (solid line) and 5-FU plus Leucovorin (dashed line). The x-axis represents months since randomization, ranging from 0 to 96, and the y-axis represents survival probability from 0.0 to 1.0. The chart includes a table of patients at risk over time for both groups.*

FDA Label Image

Figure2 (Figure2)

A Kaplan-Meier survival curve comparing two treatment groups over time in months since randomization. The solid line represents Capecitabine and the dashed line represents 5-FU plus Leucovorin. The y-axis shows survival probability, ranging from 0.0 to 1.0, while the x-axis displays months since randomization, spanning from 0 to 96 months. Below the graph, the number of patients at risk for each group is tabulated at multiple time points.*

FDA Label Image

Figure3 (Figure3)

A survival curve graph showing estimated probability over time (days) for two treatment groups: '5-FU + Leucovorin (Mayo Regimen)' represented by a dashed line, and 'Capecitabine 1250 (mg/sqm twice daily) Intermittent' represented by a solid line. The x-axis represents time in days, and the y-axis represents estimated probability. A vertical arrow marks the point at approximately 391-392 days, intersecting with a horizontal dashed line at about 0.5 probability.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier survival curve comparing estimated probability over time (days) for two groups: Docetaxel 100 mg/sqm every 3 weeks and Capecitabine 1250 mg/sqm twice daily intermittently combined with docetaxel 75 mg/sqm every 3 weeks. The graph shows survival probability declining over time up to approximately 700 days.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier survival curve comparing estimated probabilities over time in days for two treatment groups: Capecitabine 1250 mg/sqm twice daily with intermittent Docetaxel 75 mg/sqm every 3 weeks (solid line) and Docetaxel 100 mg/sqm every 3 weeks (dashed line). The graph shows survival probability on the y-axis against time on the x-axis, with median survival indicated around 351 and 442 days for the groups.*

FDA Label Image

Figure6 (Figure6)

A Kaplan-Meier survival curve chart comparing estimated probability over time (days) between two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily with intermittent Docetaxel 75 mg/sqm every 3 weeks (solid line). The chart includes median survival time markers at approximately 351.5 and 442 days for each group respectively.*

FDA Label Image

Structure (Structure)

Chemical structure of capecitabine, illustrating its molecular arrangement including fluorine, oxygen, nitrogen, carbon, and hydrogen atoms in its oral tablet form as per the product information from Quallent Pharmaceuticals Health LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.